Meeting
2020 Gastrointestinal Cancers Symposium
Identification of the optimal patients for trifluridine/tipiracil (FTD/TPI) treatment in mCRC: A Spanish real-world analysis.
Authors
Ana Fernandez Fernandez Montes
Complejo Hospitalario Universitario Ourense, Ourense, Spain
Ana Fernandez Fernandez Montes , Francisca Vazquez Rivera , Nieves Martinez Lago , Marta Covela Rúa , Antia Cousillas Castiñeiras , Paula Gonzalez Villarroel , Juan De la camara , Carlos Méndez Méndez , Mercedes Salgado Fernandez , Sonia Candamio Folgar , Margarita Reboredo Lopez , Marta Carmona Campos , Elena Gallardo Martin , Monica Jorge Fernandez , Maria Luz Pellon Augusto , Jesus Garcia Gomez Sr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 146)
Abstract #
146
Poster Bd #
G10
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Exploratory analysis of the effect of FTD/TPI in patients treated in RECOURSE by prognostic factors.
First Author: Josep Tabernero
Poster
2018 Gastrointestinal Cancers Symposium
Baseline factors associated with acute progression of metastatic lesions after primary tumor resection in patients with unresectable colorectal cancer.
First Author: Momoko Akashi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The TGF-beta pathway alterations in young-onset colorectal cancer.
First Author: Deniz Can Guven
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Fruquintinib with PD-1 inhibitors versus TAS-102 with bevacizumab in late-line mCRC: A retrospective cohort study based on propensity score matching.
First Author: Rongrong Li